Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Glenmark Pharmaceuticals is a Mumbai-based generics and specialty company with strengths in dermatology, respiratory and cardiac therapies, selling branded generics in India and emerging markets and generic formulations in the US and Europe. It sold majority control of API arm Glenmark Life Sciences to the Nirma group in 2023 to deleverage, and its innovation unit Ichnos pursues novel biologics. India branded business is the most profitable segment.
A top-15 player in the Indian domestic formulations market with leadership positions in dermatology and respiratory.
Glenmark Pharmaceuticals Ltd. is a constituent of NIFTY 200, NIFTY 500, NIFTY HEALTHCARE, NIFTY MIDCAP 100, NIFTY MIDCAP 150, NIFTY PHARMA. See where it sits on the market heatmap →
Consolidated annual figures taken from Glenmark Pharmaceuticals Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 48.26 | 37.11 | -53.22 |
| Book value / share (₹) | 372.49 | 313.59 | 278.09 |
| Return on equity | 0.0% | 11.8% | -19.1% |
| Return on capital employed | 29.6% | 18.5% | 7.2% |
| Operating margin | 23.6% | 14.0% | 5.2% |
| Net margin | 8.0% | 7.9% | -12.1% |
| EBITDA | ₹4,572 Cr | ₹2,351 Cr | ₹1,195 Cr |
| Free cash flow | ₹2,087 Cr | ₹-1,577 Cr | ₹-1,164 Cr |
| Total debt | ₹0 Cr | ₹2,194 Cr | ₹991 Cr |
| Debt to equity | 0.00 | 0.25 | 0.13 |
| Interest coverage | 19.2 | 9.0 | 1.2 |
| Current ratio | 1.77 | 1.56 | 1.28 |
| Shares outstanding | 28,22,00,000 | 28,21,90,000 | 28,21,90,000 |
Open the full income statement, balance sheet and cash flow for GLENMARK →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.